Sven O Skouby

Summary

Country: Denmark

Publications

  1. ncbi Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, Denmark
    Am J Obstet Gynecol 186:969-77. 2002
  2. ncbi On the route to combined evidence from OC and HRT/ERT
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark
    Eur J Contracept Reprod Health Care 7:185-98. 2002
  3. ncbi Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy
    Sven O Skouby
    Frederiksberg Hospital, Department of Ob Gyn, 2000 Copenhagen F, Denmark
    Maturitas 51:8-14. 2005
  4. ncbi The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy
    Anne Gompel
    Frederiksberg Hospital, Department of Ob Gyn, 2000 Copenhagen F, Denmark
    Maturitas 56:227-9. 2007
  5. ncbi Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women
    David F Archer
    Department of Obstetrics and Gynecology, Contraceptive Research and Development Program Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Fertil Steril 88:866-78. 2007
  6. ncbi A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark
    Contraception 71:111-7. 2005
  7. ncbi Consequenses for HRT following the HERS II and WHI reports: the primum non nocere is important, but translation into quo vadis is even more essential
    Sven Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, Copenhagen University Hospital, DK 2000 Copenhagen F, Denmark
    Acta Obstet Gynecol Scand 81:793-8. 2002
  8. ncbi Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy
    Sven O Skouby
    Frederiksberg Hospital, Ob Gyn, Ndr Fasanvej, 200 F Copenhagen, Denmark
    Maturitas 48:19-25. 2004
  9. ncbi Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses' Health Study
    Anne Gompel
    Frederiksberg Hospital, Department of OB/GYN, 2000 Frederiksberg F, Denmark
    Maturitas 55:1-4. 2006
  10. ncbi Progestins in HRT: sufferance or desire?
    Sven O Skouby
    Department of Obstetrics and Gynecology, Herlev University Hospital, Faculty of Health Sciences, 63 C7F Herlev Ringvej, Herlev, Denmark
    Maturitas 62:371-5. 2009

Detail Information

Publications18

  1. ncbi Hormone replacement therapy: estrogen and progestin effects on plasma C-reactive protein concentrations
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, Denmark
    Am J Obstet Gynecol 186:969-77. 2002
    ..However, the clinical significance should be viewed from the perspective of changes in other inflammatory risk markers of importance for the evolution of cardiovascular disease...
  2. ncbi On the route to combined evidence from OC and HRT/ERT
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark
    Eur J Contracept Reprod Health Care 7:185-98. 2002
  3. ncbi Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy
    Sven O Skouby
    Frederiksberg Hospital, Department of Ob Gyn, 2000 Copenhagen F, Denmark
    Maturitas 51:8-14. 2005
    ..In contrast, urogenital symptoms may be addressed efficiently and safely with long-term local estrogen therapy...
  4. ncbi The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy
    Anne Gompel
    Frederiksberg Hospital, Department of Ob Gyn, 2000 Copenhagen F, Denmark
    Maturitas 56:227-9. 2007
    ..They confirm that the increase of breast cancer diagnosis under EP is only significant after a cumulative use of more than 5 years but suggest that there is no increased risk by E within 10 years...
  5. ncbi Tibolone histology of the endometrium and breast endpoints study: design of the trial and endometrial histology at baseline in postmenopausal women
    David F Archer
    Department of Obstetrics and Gynecology, Contraceptive Research and Development Program Clinical Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507, USA
    Fertil Steril 88:866-78. 2007
    ..To address the endometrial safety of tibolone...
  6. ncbi A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark
    Contraception 71:111-7. 2005
    ..To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives...
  7. ncbi Consequenses for HRT following the HERS II and WHI reports: the primum non nocere is important, but translation into quo vadis is even more essential
    Sven Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, Copenhagen University Hospital, DK 2000 Copenhagen F, Denmark
    Acta Obstet Gynecol Scand 81:793-8. 2002
    ....
  8. ncbi Climacteric medicine: European Menopause and Andropause Society (EMAS) statements on postmenopausal hormonal therapy
    Sven O Skouby
    Frederiksberg Hospital, Ob Gyn, Ndr Fasanvej, 200 F Copenhagen, Denmark
    Maturitas 48:19-25. 2004
    ....
  9. ncbi Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses' Health Study
    Anne Gompel
    Frederiksberg Hospital, Department of OB/GYN, 2000 Frederiksberg F, Denmark
    Maturitas 55:1-4. 2006
    ....
  10. ncbi Progestins in HRT: sufferance or desire?
    Sven O Skouby
    Department of Obstetrics and Gynecology, Herlev University Hospital, Faculty of Health Sciences, 63 C7F Herlev Ringvej, Herlev, Denmark
    Maturitas 62:371-5. 2009
    ..With special reference to cardiovascular disease this review therefore makes a plea for differentiating between the array of chemically and functionally distinct progestins used therapeutically after the menopause in combination therapy...
  11. ncbi A comparative study of the effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on blood coagulability
    Sven O Skouby
    Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, Denmark
    Hum Reprod 22:1186-91. 2007
    ..Tibolone has pharmacodynamic properties different from other hormone preparations. We compared the effect of a combined HT and tibolone on the inhibition of haemostasis...
  12. ncbi [Hormone replacement therapy in menopause and cardiovascular disease]
    Anette Tønnes Pedersen
    H S Hvidovre Hospital, gynaekologisk obstetrisk afdeling
    Ugeskr Laeger 164:3973-4. 2002
  13. ncbi Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin
    Markku Ahotupa
    MCA Research Laboratory, Department of Physiology, University of Turku, Turku, Finland
    Ann Med 36:278-84. 2004
    ..Recent studies show that LDL oxidation in vitro is effectively prevented by estrogen. Yet, the effect of hormonal therapy (HT) on in vivo LDL oxidation has remained open...
  14. ncbi [Postmenopausal hormone replacement therapy--is there a cause of worry?]
    Sven O Skouby
    Ugeskr Laeger 164:3974-5. 2002
  15. ncbi A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 microg of ethinylestradiol and 100 microg of levonorgestrel with 30 microg of ethinylestradiol and 100 microg of levonorgestrel
    Jørgen Jespersen
    Department of Clinical Biochemistry, Ribe County Hospital and Department for Thrombosis Research, University of Southern Denmark, DK 6700 Esbjerg, Denmark
    Contraception 72:98-104. 2005
    ..To comparatively evaluate the impact of a balanced one-third dose-reduced oral contraceptive on hemostatic variables...
  16. ncbi Lack of difference among progestins on the anti-atherogenic effect of ethinyl estradiol: a rabbit study
    Peter Alexandersen
    Center for Clinical and Basic Research, Ballerup Byvej 222, 2750 Ballerup, Denmark
    Hum Reprod 18:1395-403. 2003
    ..The aim of this study was to investigate the influence of different oral contraceptive formulations on the development of experimental atherosclerosis and vascular reactivity...
  17. ncbi [Hormone therapy and cardiovascular disease after menopause. Myths and realities]
    Sven O Skouby
    Ugeskr Laeger 165:3907. 2003
  18. ncbi Associations between aortic calcification and components of body composition in elderly men
    Peter Alexandersen
    Center for Clinical and Basic Research A S, Ballerup Byvej 222, DK 2750 Ballerup, Denmark
    Obesity (Silver Spring) 14:1571-8. 2006
    ..To investigate associations among body composition, cardiovascular risk factors, and atherosclerosis in middle-aged and elderly men for the identification of potential pathogenic links...